FDA Leadership Turmoil: Makary's Controversial Personnel Moves Signal Deeper Agency Problems

The Wall Street Journal's editorial board delivers a scathing critique of FDA Commissioner Marty Makary's management decisions, centering on the departure of Dr. Vinay Prasad and the promotion of his deputy Katherine Szarama. Prasad, a hematologist-oncologist who was brought in last May to oversee biologics, vaccines, and gene therapies, became a flashpoint of controversy by systematically rejecting rare disease therapies—decisions that drew enough White House ire to get him removed in July. However, Makary subsequently reinstated Prasad, a move the editorial board characterizes as "a blunder." Now, with Prasad's final day at the FDA on Thursday, Makary has elevated Szarama, Prasad's deputy, to replace him.

The editorial's real target isn't just personnel instability—it's the broader leadership question at the FDA itself. The board suggests the fundamental problem runs deeper than individual appointees: "Maybe the bigger problem at the FDA is Dr. Makary." This framing implies that Makary's judgment in hiring, retaining, and promoting staff reflects questionable decision-making at the helm of the agency. The piece captures a moment of institutional dysfunction, where high-profile rejections of rare disease therapies and internal power struggles suggest the FDA may be operating without clear strategic direction or appropriate leadership.